Dare Bioscience Investor Presentation Deck
Daré Portfolio - The Big Ideas*
Contraception
Ovaprene - 1st Hormone-free, Monthly Contraceptive
Ⓡ
ADARE-204/214 - 1st 6 & 12-Month Injectable Contraceptive
DARE-LARC1 - 1st Long-Acting, Reversible Personal Contraceptive
System
DARE-RH1 - Hormone-free contraceptive target for women and men
Sexual Health
Sildenafil Cream, 3.6%
- 1st Topical cream, same active ingredient as Viagra®
- Potential first-in-category treatment for female sexual arousal
disorder (FSAD)
Vaginal Health
XACIATOTM - Clindamycin phosphate vaginal gel, 2%, treatment for
bacterial vaginosis, single dose vaginal administration^
DARE-HRT1 - 1st Hormone therapy estradiol+progesterone monthly
intravaginal ring (IVR)
DARE-VVA1 - 1st Hormone-free vaginal atrophy therapy for women
with HR+ breast cancer
DARE-GML - Novel multi-target antimicrobial
Fertility
DARE-FRT1/PTB1
- Progesterone delivery for pregnancy maintenance including the
prevention of preterm birth (DARE-PTB1) and for luteal phase
support as part of an IVF regimen (DARE-FRT1).
- 1st IVR designed to release bio-identical progesterone over 14 days
^ See Full Prescribing Information
* The product candidates presented are in clinical or preclinical stage development and none are approved
for use outside of a clinical trial. XACIATO is our only FDA approved product.
6View entire presentation